Futrakul Narisa, Futrakul Prasit
Department of Physiology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Ren Fail. 2008;30(4):353-6. doi: 10.1080/08860220801947413.
Renal microvascular disease and tubulointerstitial fibrosis are usually demonstrated in aging in humans and animals. It has recently been proposed that renal microvascular disease is the crucial determinant of tubulointerstitial disease or fibrosis. Enhanced circulating endothelial cell loss is a biomarker that reflects glomerular endothelial injury or renal microvascular disease, and fractional excretion of magnesium (FE Mg) is a sensitive biomarker that reflects an early stage of tubulointerstitial fibrosis. In aging in humans, both of these biomarkers are abnormally elevated. In addition, a glomerular endothelial dysfunction determined by altered hemodynamics associated with peritubular capillary flow reduction is substantiated. A correction of such hemodynamic alteration with vasodilators can effectively improve renal perfusion and restore renal function. Thus, anti-aging therapy can reverse the renal microvascular disease and dysfunction associated with the aging process.
肾微血管疾病和肾小管间质纤维化通常在人类和动物衰老过程中出现。最近有人提出，肾微血管疾病是肾小管间质疾病或纤维化的关键决定因素。循环内皮细胞损失增加是反映肾小球内皮损伤或肾微血管疾病的生物标志物，而镁的分数排泄（FE Mg）是反映肾小管间质纤维化早期阶段的敏感生物标志物。在人类衰老过程中，这两种生物标志物都会异常升高。此外，由与肾小管周围毛细血管血流减少相关的血流动力学改变所决定的肾小球内皮功能障碍也得到了证实。用血管扩张剂纠正这种血流动力学改变可以有效改善肾灌注并恢复肾功能。因此，抗衰老疗法可以逆转与衰老过程相关的肾微血管疾病和功能障碍。
